Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs PRME: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: LCTX 3 – 2 PRME (1 Tie) Matrix Metrics: LCTX 7 – 3 PRME

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Prime Medicine, Inc. (PRME) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas PRME carries 41.2/100 (SELL) at $3.84 (N/M Forward P/E, -2584.2% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. PRME 41.2/100 SELL) and 1.36β · 79% Vol risk profile, whereas PRME leads top-line expansion (+243.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile PRME is in a Breakdown options structure phase (RSI 46.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs PRME
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
PRME NASDAQ
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.84
+0.52% 1D
Market Cap $851.8M
TTM Revenue $7.1M
Forward P/E N/M
Beta / 30D Vol 2.48β · 149% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 15.0 Fund 45.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.6 · SMA20: $4.32 · SMA50: $3.73

6-Pillar Scorecard Institutional Category Breakdown (LCTX 3 – 2 PRME)

Columns: Metric · LCTX · PRME
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 16.3x 129.8x
2. Growth & Scale PRME
Revenue Growth (YoY) -61.0% +243.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $7.1M
Market Cap $212.1M $851.8M
3. Profitability & Quality LCTX
Gross Margin -95.0% N/A
Operating Margin -280.3% -2584.2%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -207.2%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$157M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $65M Net Debt (0.06x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRME
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 896.2% (100th %ile) 444.0% (64th %ile)
Put/Call OI Skew 1.10x (Balanced) 0.50x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (7) vs PRME (3)
Institutional Metric LCTX PRME Criterion Row Edge
Market Capitalization
Scale
$212.1M $851.8M Larger Scale PRME
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% +243.9% Higher Growth PRME
Operating Margin (TTM)
Profitability
-280.3% -2584.2% Higher Margin LCTX
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -207.2% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 36% ($3–$6) Stronger Trend PRME
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 2.48β · 149% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $7.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · 129.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$157M ($65M Net Debt (0.06x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRME +14.61 pp
LCTX: -13.82% · PRME: +0.79%
3M Horizon PRME +37.34 pp
LCTX: -24.07% · PRME: +13.27%
6M Horizon PRME +68.05 pp
LCTX: -37.88% · PRME: +30.17%
1Y Horizon PRME +61.84 pp
LCTX: -53.67% · PRME: +8.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue PRME Revenue LCTX Op. Margin PRME Op. Margin Margin Leader
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $10M -1448.4% -17.9% PRME
FY2021 $0M N/A -1133.6% N/A LCTX
FY2022 $10M N/A -153.2% N/A LCTX
FY2023 $10M N/A -276.5% N/A LCTX
FY2024 $10M $0M -226.1% -6787.4% LCTX
FY2025 $10M $0M -251.6% -4498.1% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRME BREAKDOWN
15d in phase · OBV DISTRIBUTION
Current IV 444.0%
IV Percentile 64th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PRME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRME Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $851.8M market capitalization and -2584.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs PRME Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Prime Medicine, Inc. (PRME) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas PRME carries 41.2/100 (SELL) at $3.84 (N/M Forward P/E, -2584.2% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. PRME 41.2/100 SELL) and 1.36β · 79% Vol risk profile, whereas PRME leads top-line expansion (+243.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile PRME is in a Breakdown options structure phase (RSI 46.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PRME leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with PRME at +243.9% YoY revenue growth and +0.0% YoY earnings growth on $7.1M TTM revenue (N/A gross margin, -2584.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while PRME shifted N/A. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRME.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas PRME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 129.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus PRME (-207.2% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, PRME carries 444.0% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.48β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.